- Home
- BOLD vs KALA Comparison
BOLD vs KALA Comparison
Compare BOLD & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOLD
- KALA
- Stock Information
- Founded
- BOLD 2018
- KALA 2009
- Country
- BOLD United States
- KALA United States
- Employees
- BOLD N/A
- KALA N/A
- Industry
- BOLD
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- BOLD
- KALA Health Care
- Exchange
- BOLD Nasdaq
- KALA Nasdaq
- Market Cap
- BOLD 24.4M
- KALA 26.2M
- IPO Year
- BOLD 2024
- KALA 2017
- Fundamental
- Price
- BOLD $1.15
- KALA $19.25
- Analyst Decision
- BOLD Buy
- KALA Strong Buy
- Analyst Count
- BOLD 4
- KALA 3
- Target Price
- BOLD $4.00
- KALA $25.00
- AVG Volume (30 Days)
- BOLD 77.7K
- KALA 279.1K
- Earning Date
- BOLD 11-06-2025
- KALA 11-11-2025
- Dividend Yield
- BOLD N/A
- KALA N/A
- EPS Growth
- BOLD N/A
- KALA N/A
- EPS
- BOLD N/A
- KALA N/A
- Revenue
- BOLD N/A
- KALA N/A
- Revenue This Year
- BOLD N/A
- KALA N/A
- Revenue Next Year
- BOLD N/A
- KALA N/A
- P/E Ratio
- BOLD N/A
- KALA N/A
- Revenue Growth
- BOLD N/A
- KALA N/A
- 52 Week Low
- BOLD $1.00
- KALA $2.92
- 52 Week High
- BOLD $4.72
- KALA $19.69
- Technical
- Relative Strength Index (RSI)
- BOLD 49.88
- KALA 87.22
- Support Level
- BOLD $1.13
- KALA $13.14
- Resistance Level
- BOLD $1.16
- KALA $15.66
- Average True Range (ATR)
- BOLD 0.04
- KALA 1.69
- MACD
- BOLD 0.00
- KALA 0.64
- Stochastic Oscillator
- BOLD 55.56
- KALA 96.10
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.